Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 168Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Recurrence 28Leukemia 24Vomiting 23Neoplasms, Plasma Cell 20Lymphoma 18Neoplasms 16Nausea 13Burkitt Lymphoma 11Prostatic Neoplasms 8Immunoglobulin Light-chain Amyloidosis 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Follicular 5Lung Neoplasms 5Hodgkin Disease 5Ovarian Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Leukemia, Biphenotypic, Acute 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Paraproteinemias 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

fosaprepitant 1Prochlorperazine 1Preoperative Exercise 1Ondansetron 1Olanzapine 1Neurokinin-1 Receptor Antagonists 1FloSeal Matrix 1Ferric Oxide, Saccharated 1Enhanced Recovery After Surgery 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gynecologic Cancer × Dexamethasone × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡